144 related articles for article (PubMed ID: 36139541)
1. In Vivo Application of CRISPR/Cas9 Revealed Implication of
Cai H; Agersnap SN; Sjøgren A; Simonsen MK; Blaavand MS; Jensen UV; Thomsen MK
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139541
[TBL] [Abstract][Full Text] [Related]
2. Integrative analysis of FOXP1 function reveals a tumor-suppressive effect in prostate cancer.
Takayama K; Suzuki T; Tsutsumi S; Fujimura T; Takahashi S; Homma Y; Urano T; Aburatani H; Inoue S
Mol Endocrinol; 2014 Dec; 28(12):2012-24. PubMed ID: 25329375
[TBL] [Abstract][Full Text] [Related]
3. FOXA1 knock-out via CRISPR/Cas9 altered Casp-9, Bax, CCND1, CDK4, and fibronectin expressions in LNCaP cells.
Albayrak G; Konac E; Ugras Dikmen A; Bilen CY
Exp Biol Med (Maywood); 2018 Aug; 243(12):990-994. PubMed ID: 30043639
[TBL] [Abstract][Full Text] [Related]
4. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes.
Adams EJ; Karthaus WR; Hoover E; Liu D; Gruet A; Zhang Z; Cho H; DiLoreto R; Chhangawala S; Liu Y; Watson PA; Davicioni E; Sboner A; Barbieri CE; Bose R; Leslie CS; Sawyers CL
Nature; 2019 Jul; 571(7765):408-412. PubMed ID: 31243370
[TBL] [Abstract][Full Text] [Related]
5. Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation.
Gao N; Ishii K; Mirosevich J; Kuwajima S; Oppenheimer SR; Roberts RL; Jiang M; Yu X; Shappell SB; Caprioli RM; Stoffel M; Hayward SW; Matusik RJ
Development; 2005 Aug; 132(15):3431-43. PubMed ID: 15987773
[TBL] [Abstract][Full Text] [Related]
6. Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia.
Banham AH; Boddy J; Launchbury R; Han C; Turley H; Malone PR; Harris AL; Fox SB
Prostate; 2007 Jul; 67(10):1091-8. PubMed ID: 17477366
[TBL] [Abstract][Full Text] [Related]
7. The expression and correlation between the transcription factor FOXP1 and estrogen receptors in epithelial ovarian cancer.
Hu Z; Zhu L; Tan M; Cai M; Deng L; Yu G; Liu D; Liu J; Lin B
Biochimie; 2015 Feb; 109():42-8. PubMed ID: 25500588
[TBL] [Abstract][Full Text] [Related]
8. FOXP1 and estrogen signaling in breast cancer.
Ijichi N; Ikeda K; Horie-Inoue K; Inoue S
Vitam Horm; 2013; 93():203-12. PubMed ID: 23810008
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis.
Jin HJ; Zhao JC; Ogden I; Bergan RC; Yu J
Cancer Res; 2013 Jun; 73(12):3725-36. PubMed ID: 23539448
[TBL] [Abstract][Full Text] [Related]
10. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer.
Parolia A; Cieslik M; Chu SC; Xiao L; Ouchi T; Zhang Y; Wang X; Vats P; Cao X; Pitchiaya S; Su F; Wang R; Feng FY; Wu YM; Lonigro RJ; Robinson DR; Chinnaiyan AM
Nature; 2019 Jul; 571(7765):413-418. PubMed ID: 31243372
[TBL] [Abstract][Full Text] [Related]
11. FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells.
Takayama K; Horie-Inoue K; Ikeda K; Urano T; Murakami K; Hayashizaki Y; Ouchi Y; Inoue S
Biochem Biophys Res Commun; 2008 Sep; 374(2):388-93. PubMed ID: 18640093
[TBL] [Abstract][Full Text] [Related]
12. SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.
Hernández-Llodrà S; Segalés L; Safont A; Juanpere N; Lorenzo M; Fumadó L; Rodríguez-Vida A; Cecchini L; Bellmunt J; Lloreta-Trull J
Prostate; 2019 Jul; 79(10):1156-1165. PubMed ID: 31090082
[TBL] [Abstract][Full Text] [Related]
13. Pioneer of prostate cancer: past, present and the future of FOXA1.
Teng M; Zhou S; Cai C; Lupien M; He HH
Protein Cell; 2021 Jan; 12(1):29-38. PubMed ID: 32946061
[TBL] [Abstract][Full Text] [Related]
14. Upstream stimulatory factor 2, a novel FoxA1-interacting protein, is involved in prostate-specific gene expression.
Sun Q; Yu X; Degraff DJ; Matusik RJ
Mol Endocrinol; 2009 Dec; 23(12):2038-47. PubMed ID: 19846536
[TBL] [Abstract][Full Text] [Related]
15. FOXP1: a potential therapeutic target in cancer.
Koon HB; Ippolito GC; Banham AH; Tucker PW
Expert Opin Ther Targets; 2007 Jul; 11(7):955-65. PubMed ID: 17614763
[TBL] [Abstract][Full Text] [Related]
16. Gli Transcription Factors Mediate the Oncogenic Transformation of Prostate Basal Cells Induced by a Kras-Androgen Receptor Axis.
Wu M; Ingram L; Tolosa EJ; Vera RE; Li Q; Kim S; Ma Y; Spyropoulos DD; Beharry Z; Huang J; Fernandez-Zapico ME; Cai H
J Biol Chem; 2016 Dec; 291(49):25749-25760. PubMed ID: 27760825
[TBL] [Abstract][Full Text] [Related]
17. Cancer genetics and genomics of human FOX family genes.
Katoh M; Igarashi M; Fukuda H; Nakagama H; Katoh M
Cancer Lett; 2013 Jan; 328(2):198-206. PubMed ID: 23022474
[TBL] [Abstract][Full Text] [Related]
18. NFI transcription factors interact with FOXA1 to regulate prostate-specific gene expression.
Grabowska MM; Elliott AD; DeGraff DJ; Anderson PD; Anumanthan G; Yamashita H; Sun Q; Friedman DB; Hachey DL; Yu X; Sheehan JH; Ahn JM; Raj GV; Piston DW; Gronostajski RM; Matusik RJ
Mol Endocrinol; 2014 Jun; 28(6):949-64. PubMed ID: 24801505
[TBL] [Abstract][Full Text] [Related]
19. Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer.
Zhou S; Hawley JR; Soares F; Grillo G; Teng M; Madani Tonekaboni SA; Hua JT; Kron KJ; Mazrooei P; Ahmed M; Arlidge C; Yun HY; Livingstone J; Huang V; Yamaguchi TN; Espiritu SMG; Zhu Y; Severson TM; Murison A; Cameron S; Zwart W; van der Kwast T; Pugh TJ; Fraser M; Boutros PC; Bristow RG; He HH; Lupien M
Nat Commun; 2020 Jan; 11(1):441. PubMed ID: 31974375
[TBL] [Abstract][Full Text] [Related]
20. The essential role of GATA transcription factors in adult murine prostate.
Xiao L; Feng Q; Zhang Z; Wang F; Lydon JP; Ittmann MM; Xin L; Mitsiades N; He B
Oncotarget; 2016 Jul; 7(30):47891-47903. PubMed ID: 27374105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
